April 13, 2015 / 3:03 PM / 3 years ago

BUZZ-U.S. STOCKS ON THE MOVE-Builders FirstSource, Great Basin

(For faster updates on individual market-movers, Eikon users please use search string "STXBZ US"; for the Day Ahead newsletter, link.reuters.com/mex49s; for the Morning News Call newsletter, link.reuters.com/nex49s) The Dow and S&P 500 were little changed in morning trading on Monday after three straight days of gains as the corporate earnings season was poised to kick into high gear with a slew of reports this week. The Dow Jones industrial average was up 0.11 percent at 18,077.41 and the S&P 500 was up 0.10 percent at 2,104.12.

** BUILDERS FIRSTSOURCE INC, $10.8, +56.52 pct

The building products supplier said it will buy privately held ProBuild Holdings LLC for $1.63 billion in cash.

** GREAT BASIN SCIENTIFIC INC, $4.63, +57.48 pct

The diagnostic test maker said it recorded 101 customers using its sample-to-result molecular diagnostic technology in the United States in the first quarter, up from 84 in the preceding quarter.

** ORAMED PHARMACEUTICALS INC, $7.384, +18.52 pct

MLV & Co analyst Raghuram Selvaraju assumed coverage on the Israel-based drug developer’s stock with a “buy” rating and raised price target to $30 from $27.

** ARCA BIOPHARMA INC, $1.065, +26.80 pct

The drug developer said its experimental heart drug, Gencaro, got “fast track” status from the U.S. Food and Drug Administration.

** ALAMOS GOLD INC, $6.23, +5.77 pct

** AURICO GOLD INC, $3.22, +7.69 pct

Canadian gold miners Alamos and AuRico said they would merge in a deal valued at about $1.5 billion, combining high-yield assets such as the Mulatos mine in Mexico and the Young-Davidson mine in Ontario, Canada.

** CLOVIS ONCOLOGY INC, $88.13, +13.86 pct

Analysts at Goldman Sachs upgraded the cancer drug developer’s stock to “buy” from “neutral” and also raised their price target to $117 from $68.

** AETERNA ZENTARIS INC, $0.5516, +7.09 pct

The Canadian drug developer said it plans to conduct a confirmatory study on hormone deficiency drug-test after meeting with the U.S. Food and Drug Administration.


The solar module maker said it had started supplying panels and other products for Silent Falcon UAS Techonologies’ unmanned solar-powered aircraft.

** ARROWHEAD RESEARCH CORP, $8.3626, +5.72 pct

The drug developer said the U.S. Food and Drug Administration has allowed it to begin a multiple-dose mid-stage study on its hepatitis B drug, ARC-520.

** CIPHER PHARMACEUTICALS INC, $11.05, +14.04 pct

The Canadian drug developer said it acquired privately held dermatology company Innocutis Holdings LLC for $45.5 million in cash to enter the U.S. commercial market.

** NETFLIX INC, $478.16, +5.19 pct

Analysts at UBS upgraded the streaming video service provider’s stock to “buy” from “neutral”.

** SINA CORP, $35.28, -5.95 pct

China will punish the web portal and social media firm after it was identified as operating the most complained about major website in the country, the Internet regulator said on Friday, the latest blow in an ongoing online crackdown.

** CAPSTONE TURBINE CORP, $0.6401, +4.03 pct

The microturbine energy systems maker said on Friday it was reorganizing to lower operating costs and eliminating three executive positions to save estimated $2 million annually.

** THE MEDICINES CO, $29.41, +3.89 pct

An intravenous blood clot preventer developed by the biotech company should be approved by the U.S. Food and Drug Administration, FDA staff reviewers concluded.

** SYMANTEC CORP, $24.8, -3.05 pct

The security software maker has been seeking buyers for its storage software business, Veritas, or the entire company for several months, sources familiar with the matter said. (Compiled by Anannya Pramanick in Bengaluru; Edited by Maju Samuel)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below